RxDoctor Payments DataLook up a doctor →

Lourdes Aponte, MD

Rheumatology · Lewes, DENPI 1144299959

Payments from drug & device makers

$19,728in general payments, 2019–2025

Across 959 payments — averaging $20.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3K
  • Johnson & Johnson$2K
  • AbbVie$2K
  • Lilly USA, LLC$2K
  • Mallinckrodt Hospital Products Inc.$1K
  • AstraZeneca$1K
  • plus $8K from 43 others

What the payments were for

  • Grants$2401%
  • Food & beverage$18,73195%
  • Education$7584%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few rheumatology providers in Delawareto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$5,954,829
Medicare patients
1,442
Services billed
405,872

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab51$443,077
Enbrel MiniEtanercept25$255,271
Enbrel SureclickEtanercept11$209,540
Humira(Cf)Adalimumab25$183,413
Xeljanz XrTofacitinib Citrate29$162,861
OzempicSemaglutide48$100,200
Orencia ClickjectAbatacept16$94,175
Cimzia (2 Pack)Certolizumab Pegol13$74,964
Taltz AutoinjectorIxekizumab11$74,852
XeljanzTofacitinib Citrate12$69,135
JardianceEmpagliflozin40$49,362
EliquisApixaban31$37,746
FarxigaDapagliflozin Propanediol29$37,376
Repatha SureclickEvolocumab17$27,574
Hydroxychloroquine Sulfate446$27,169

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira(Cf), Savella, Linzess$2,322$211,79262 claims
PfizerXeljanz, Eliquis$1,115$106,88143 claims
Novo NordiskOzempic$342$100,20048 claims
UCB, Inc.Cimzia (2 Pack)$966$74,96413 claims
Boehringer IngelheimJardiance$337$49,36240 claims
AstraZenecaFarxiga$1,145$37,37629 claims
Astellas Pharma US IncMyrbetriq$179$26,61032 claims
GSKTrelegy Ellipta$462$17,19617 claims
MerckJanumet$34$9,09015 claims
Idorsia Pharmaceuticals US IncQuviviq$180$7,92017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few rheumatology providers in Delawareon file to place this against a meaningful peer group, so we don't.

Other rheumatology in Lewes

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →